Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-…

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain…

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways altered in these…

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal…

Here are a few notable presentations from Day 3. BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE…

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that…